Instructions:

  • Need to find an article to delete/replace Article #4 (has too many NE; can only have a max of 1)
  • Need to also delete the PR outcome section; does not match any of the other articles
  • New article will need to address current outcomes, with the exception of PR
  • Due by Sept 18th at 7pm Central/Standard time

PICOT: In adult psychiatric patients, who are discharged, will prescribing long-acting antipsychotic injectables vs oral antipsychotics increase compliance vs relapse thus reducing rates or re-hospitalization?  

    Team Members:  (1, 7, 8);             (2, 3, 6);         (4 ,5, 9) – My articles

    Add the team members names above, in parenthesis place the number of the article that correlates with each team member’s name in the table below.

    i.e. Jane Doe (2,4)

Levels of Evidence Synthesis Table

X (copy symbol as needed)123456789
Level  I: Systematic review or meta-analysis    X     X         X   
Level  II: Randomized controlled trial                  
Level  III: Controlled trial without randomization                  
Level  IV: Case-control or cohort studyX X     X    X       
Level V: Systematic review of qualitative or descriptive studies                  
Level VI: Qualitative or descriptive study, CPG,
Lit Review, QI or EBP project		               X   
Level  VII: Expert opinion            X     

LEGEND 1 = MacEwan et. al. (2016); 2 = Sajatovic et al. (2017); 3 = Ostuzzi et al. (2017); 4 = Olayinka et al. (2019); 5 = Kishimoto et al. (2014); 6= Green et al. (2017), 7 = Llorca et al. (2013); 8 = Das et al. (2014), 9 = Zhornitsky et al. (2012) 

        PICOT: In adult psychiatric patients, who are discharged, will prescribing long-acting antipsychotic injectables vs oral antipsychotics increase compliance vs relapse thus reducing rates or re-hospitalization? 

Team Members:   (1, 7, 8);           (2, 3, 6);              (4, 5, 9) – My articles

        Add the team members names above, in parenthesis place the number of the article that correlates with each team member’s name in the table below.

        i.e. Jane Doe (2,4)

        Outcomes Synthesis Table

Ÿ,  , —, NE, NR, P
(select symbol and copy as needed)		123456789
MC  ↑  ↑    ↑  NE         _      ↑    ✓   ✓   ↑ 
RR ↓    ↓       ↓   NE       _       NE  NE ✓   ↓  
ME NE  NE    ↑  NE        ↑ ↑       ✓  ✓  ↑  
RHR  ↓  ↓     ↓   _    ↓  NE NE  NE ↓ 
PR  NE  NE NE ↑  NE NE   NE  NE   NE 

SYMBOL KEY

↑ = Increased, ↓ = Decreased, — = No Change, NE = Not Examined, NR = Not Reported, ✓ = applicable or present

LEGEND

MC = medication compliance; RR = relapse rate; ME = medication effectiveness; RHR = Re-hospitalization Rate, PR = prescription rate  

 

References 

Das, A. K., Malik, A., & Haddad, P. M. (2014). A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting          injections. Therapeutic advances in psychopharmacology, 4(5), 179-185.  

Greene, M., Burudpakdee, C., Seetasith, A., Behling, M., & Krasa, H. (2018). Evaluation of patient support program and adherence to long-acting injectable  aripiprazole for patients utilizing injection local care centers. Current Medical Research and Opinion, 35(1), 97-103.   doi:10.1080/03007995.2018.1536651 

Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014). Long-acting injectable vs  oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophrenia Bulletin, 40(1),       192–213.          https://doi.org/10.1093/schbul/sbs150 

Llorca,P.M.,Abbar,M.,Courtet,P.,Guillaume,S.,Lancrenon,S.,& Samalin, L. (2013). Guidelines for the use and management of long-acting injectable antipsychotics      in serious mental illness. BMC  psychiatry, 13(1), 340.  

MacEwan, J. P., Kamat, S. A., Duffy, R. A., Seabury, S., Chou, J. W., Legacy, S. N., ... & Karson, C. (2016). Hospital readmission rates among patients with   schizophrenia treated with long-acting   injectables or oral antipsychotics. Psychiatric Services, 67(11), 1183-1188.

Olayinka, O., Oyelakin, A., Cherukupally, K., Virk, I., Ojimba, C., Khadka, S., … Hershberger, J. (2019). Use of long-acting injectable antipsychotic in an       inpatient unit of a community teaching hospital. Psychiatry Journal, 2019, 1–5. doi: 10.1155/2019/8629030 

Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2017). Does formulation matter? A systematic review and meta-analysis of oral versus long     acting antipsychotic studies. Schizophrenia Research, 183, 10-21. doi:10.1016/j.schres.2016.11.010          

Sajatovic, M., Ramirez, L. F., Fuentes-Casiano, E., Cage, J., Tatsuoka, C., Aebi, M. E., . . . Levin, J. B.    (2017). A 6-Month prospective trial of a personalized           behavioral intervention long-acting injectable antipsychotic in individuals with schizophrenia at risk of treatment nonadherence and homelessness.        Journal of Clinical Psychopharmacology, 37(6), 702-707. doi:10.1097/jcp.0000000000000778 

Zhornitsky, S., & Stip, E. (2012). Oral versuslong-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for    treatment nonadherence: A systematic review. Schizophrenia Research and Treatment, 2012, 1–12. https://doi.org/10.1155/2012/407171